Cellular Biology |
From the Naval Medical Research Center (R.M.M.C., Y.O.), Bethesda, Md; Department of Neurosurgery (F.A.L.), Johns Hopkins University School of Medicine, Baltimore, Md; Hebrew University (E.S., R.M.), Jerusalem, Israel; Stroke Branch (Y.C., J.B., N.A., M.S.), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Md.
Correspondence to Maria Spatz, MD, National Institutes of Health, NINDS, Stroke Branch, 36 Convent Dr, MSC 4128, Bethesda, MD 20892-4128. E-mail spatzm{at}ninds.nih.gov
AbstractIn brain, the regulatory mechanism of the endothelial reactivity to nitric oxide and endothelin-1 may involve Ca2+, cytoskeleton, and vasodilator-stimulated phosphoprotein changes mediated by the cGMP/cGMP kinase system.1 Endothelium of human brain capillaries or microvessels is used to examine the interplay of endothelin-1 with the putative vasorelaxant 2-arachidonoyl glycerol, an endogenous cannabimimetic derivative of arachidonic acid. This study demonstrates that 2-arachidonoyl glycerol counteracts Ca2+ mobilization and cytoskeleton rearrangement induced by endothelin-1. This event is independent of nitric oxide, cyclooxygenase, and lipoxygenase and is mediated in part by cannabimimetic CB1 receptor, G protein, phosphoinositol signal transduction pathway, and Ca2+-activated K+ channels. The induced rearrangements of cellular cytoskeleton (actin or vimentin) are partly prevented by inhibition of protein kinase C or high levels of potassium chloride. The 2-arachidonoyl glycerolinduced phosphorylation of vasodilator-stimulated phosphoprotein is mediated by cAMP. These findings suggest that 2-arachidonoyl glycerol may contribute to the regulation of cerebral capillary and microvascular function.
Key Words: brain endothelial function 2-arachidonoglycerol endothelin-1 endothelium cannabinoids
This article has been cited by other articles:
![]() |
D. J. Rademacher, S. Patel, W.-S. V. Ho, A. M. Savoie, N. J. Rusch, K. M. Gauthier, and C. J. Hillard U-46619 but not serotonin increases endocannabinoid content in middle cerebral artery: evidence for functional relevance Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2694 - H2701. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C.D. Souza, H. C. Salgado, G. Ballejo, and M. C. O. Salgado SR141716A-Sensitive Enhancement of ET-1 Hypotensive Effect by Chronic NOS Inhibition Hypertension, October 1, 2003; 42(4): 802 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Chen, R. M. McCarron, S. Golech, J. Bembry, B. Ford, F. A. Lenz, N. Azzam, and M. Spatz ET-1- and NO-mediated signal transduction pathway in human brain capillary endothelial cells Am J Physiol Cell Physiol, February 1, 2003; 284(2): C243 - C249. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Mechoulam, M. Spatz, and E. Shohami Endocannabinoids and Neuroprotection Sci. Signal., April 23, 2002; 2002(129): re5 - re5. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |